SciTegic's ISV Partner Program Welcomes Twentieth Member.

SAN DIEGO -- SciTegic, the leader in data pipelining and workflow tools, announced today that four new members have joined its Independent Software Vendor (ISV) partner program. The program's aim is to compile a collection of high value research applications to address customer needs for increased software interoperability. Through new collaborations with ACD/Labs, Bio-Rad, GeneGo, and Partek, scientists in drug discovery will obtain access to new, integrated software products that will help them solve more complex research problems in a more efficient manner.

"We are pleased to see a rapidly growing community adopt the Pipeline Pilot platform for life sciences software deployment," says Mathew Hahn, Vice President and General Manager of SciTegic. "By promoting partnerships with key scientific software vendors, we allow our customers to leverage existing, specialized software solutions in order to increase their R&D productivity."

"Our joint customers will be able to access ACD/Labs' PhysChem and Nomenclature batch software (www.acdlabs.com) from within SciTegic's Pipeline Pilot framework, leading to more efficient and repeatable discovery processes," says Antony Williams, Vice President and Chief Science Officer of ACD/Labs.

"The combination of our KnowItAll(R) technologies (www.knowitall.com/adme) for in silico ADME/Tox with SciTegic will allow drug discovery researchers to more accurately predict key properties for potential drug candidates, thus accelerating the drug discovery process," says Gregory M. Banik, Ph.D., General Manager of Bio-Rad Laboratories, Informatics.

"We are excited to deliver our technology as part of SciTegic's Pipeline Pilot platform," says Julie Bryant, Vice President of Business Development of GeneGo. "Joint customers will be able to increase their research efficiency by rapidly incorporating pathway information in their workflows."

"We are pleased to join SciTegic's ISV program," said Tom Downey, President and CEO of Partek, "as it allows us to bring together the data workflow capabilities of Pipeline Pilot with the statistics and interactive visualization capabilities that our software offers, allowing life sciences researchers to make better decisions."

About SciTegic

SciTegic, a wholly owned subsidiary of Accelrys, Inc. (NASDAQ:ACCL), develops and markets informatics software to the pharmaceutical and biotechnology industries. The company has pioneered a new technology approach called "Data Pipelining" to process research discovery data with unprecedented flexibility. This new methodology has established its utility by accelerating informatics research for thousands of users at hundreds of customer sites worldwide. Further information about SciTegic is available at: www.scitegic.com.

About Advanced Chemistry Development

Advanced Chemistry Development, Inc. (ACD/Labs) is a chemistry software company offering solutions that truly integrate chemical structures with analytical chemistry information to produce ChemAnalytics(TM). ACD/Labs creates innovative software packages that aid chemical research scientists worldwide with spectroscopic validation of structures, elucidation of unknown substances, chromatographic separation, medicinal chemistry, preformulation of novel drug agents, systematic nomenclature generation, and chemical patenting and publication. Combined, ACD/Labs' solutions create an analytical informatics system that provides dramatic feed-forward effects on the chemical and pharmaceutical research process. Founded in 1993, and headquartered in Toronto, Canada, ACD/Labs employs a team of over 100 dedicated individuals whose continual efforts carry ACD/Labs' innovative technologies into pharmaceutical, biotech, chemical, and materials companies throughout the world. Information about Advanced Chemistry Development and its products is available at www.acdlabs.com.

About Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. (www.bio-rad.com) is a multinational manufacturer and distributor of life science research products and clinical diagnostics. It is based in Hercules, California, and serves more than 70,000 research and industry customers worldwide through a network of more than 30 wholly owned subsidiary offices.

About GeneGo

GeneGo (www.genego.com) develops tools for integration and systems level analysis of high-throughput experimental data in human biology and medicinal chemistry. The MetaCore platform is a manually curated, proprietary database for systems biology. It includes genes, proteins, compounds, metabolites, ligands, transcriptional factors and hormones for human, mouse, rat, dog, chicken, chimpanzee, worm, fly and yeast. Researchers can overlay gene expression, proteomic, metabolomic, SNP and SAGE data in the context of pathways. GeneGo is developing workflows for customers using Pipeline Pilot. MetaDrug is a systems ADME/Tox platform that has been integrated with Pipeline Pilot allowing researchers to develop workflows to bring in lists of compounds, predict metabolites, prioritize them and then visualize the important metabolites in pathways to ensure that compounds that move forward have the greatest opportunity for success.

About Partek

Partek Incorporated (www.partek.com) is the maker of Partek(R) Genomics Solution(TM), Partek(R) Screener Solution(TM), Partek(R) QSAR Solution(TM), and Partek(R) Discovery Suite(TM). Partek offers software solutions designed for gene expression, copy number, HTS, QSAR and general data analysis. Partek software provides powerful statistical analysis integrated with interactive data visualization and is designed to efficiently process large volumes of high-dimensional data. Partek, headquartered in St. Louis, Missouri, also offers consulting services to assist you in making discoveries about your data.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). When used anywhere in this document, the words "expects," "believes," "anticipates," "estimates," and similar expressions are intended to identify forward-looking statements. Examples of such forward-looking statements herein include statements regarding the future success of the SciTegic ISV Program. Accelrys has based these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of Accelrys' strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of existing and potential future patent issues, additional competition, changes in economic conditions, and other risks and uncertainties described in documents Accelrys has filed with the Securities and Exchange Commission, including its most recent report on Form 10-Q. All forward-looking statements in this document are qualified entirely by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this document. These forward-looking statements speak only as of the date of this document. Accelrys claims the protection of the safe harbor for forward-looking statements contained in the Act and, disclaims any intent or obligation to publicly update or revise any forward-looking statements contained herein to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.